Phase 1 11 items
Studies
- Lepodisiran phase 1: a single 608 mg dose keeps Lp(a) 94 percent down at day 337 (Nissen et al., JAMA 2023)
- Muvalaplin, the first oral inhibitor of Lp(a) formation: phase 1 (Nicholls et al., JAMA 2023)
- Olpasiran, a GalNAc-conjugated siRNA against LPA: preclinical development and phase 1 (Koren et al., Nat Med 2022)
- First antisense drug against apo(a) in humans: ISIS-APO(a)Rx phase 1 (Tsimikas et al., Lancet 2015)
- APOLLO: single ascending doses of SLN360 (zerlasiran) lower Lp(a) by up to 98 percent (Nissen et al., JAMA 2022)
- Zerlasiran single and multiple doses in ASCVD patients: Lp(a) down 90 percent at 201 days after two doses (Nissen et al., JAMA 2024)
- Olpasiran cuts Lp(a) by up to 99% with similar effect in Japanese and non-Japanese subjects, a phase 1 dose-finding trial (Clin Ther 2022)
- Antisense oligonucleotide cuts Lp(a) by 69%, but does not affect fibrinolysis, a placebo-controlled trial of 17 patients (J Lipid Res 2019)
- ISIS-APO(a)Rx cuts Lp(a) by up to 89% in a phase 1 trial, the first drug specifically designed to lower Lp(a), a review of antisense inhibition of apo(a) (J Lipid Res 2016)
